Related references
Note: Only part of the references are listed.Critical Review of Double-Carbapenem Therapy for the Treatment of Carbapenemase-Producing Klebsiella pneumoniae
Ola Mashni et al.
ANNALS OF PHARMACOTHERAPY (2019)
Infections by multidrug- resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
Despoina Koulenti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Adding double carbapenem therapy to the armamentarium against carbapenem-resistant Enterobacteriaceae bloodstream infections
Bryan P. White et al.
INFECTIOUS DISEASES (2019)
Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae: A Single-Center, Observational Study
F. Cancelli et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2017)
Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae
M. Souli et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae : the activity of the double-carbapenem regimen is related to meropenem MIC value
A. Oliva et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L
Senthil Natesan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
Belen Gutierrez-Gutierrez et al.
LANCET INFECTIOUS DISEASES (2017)
Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae
Piergiorgio Cojutti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study
Gennaro De Pascale et al.
CRITICAL CARE (2017)
Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
Jessica B. Cprek et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Alan J. Xiao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae
A. Oliva et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study
Mario Tumbarello et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Rapid Detection of KPC, NDM, and OXA-48-Like Carbapenemases by Real-Time PCR from Rectal Swab Surveillance Samples
Tracy D. Lee et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2015)
Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence
Matthew E. Falagas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae
Helen Giamarellou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Klebsiella pneumoniae Antimicrobial Drug Resistance, United States, 1998-2010
Guillermo V. Sanchez et al.
EMERGING INFECTIOUS DISEASES (2013)
Dosing Nomograms for Attaining Optimum Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach
Federico Pea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
Zubair A. Qureshi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2012)
Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Real-time TaqMan PCR for rapid detection of genes encoding five types of non-metallo-(class A and D) carbapenemases in Enterobacteriaceae
R. L. Swayne et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Bloodstream Infections Caused by Metallo-β-Lactamase/Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae among Intensive Care Unit Patients in Greece: Risk Factors for Infection and Impact of Type of Resistance on Outcomes
Eleni Mouloudi et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis
A. J. Brink et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing enterobactefiaceae:: Report from the SENTRY antimicrobial surveillance program
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial
Samir G. Sakka et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing
DS Burgess et al.
CLINICAL THERAPEUTICS (2002)
Share Paper
